



## News Release

13 January 2025

### **Innovotech Inc. appoints Mr. Brad Clark, CPA, CBV to its Board of Directors and creates new operating subsidiary to prepare for growth.**

**Edmonton, Alberta, January 13, 2025** – The Board of Directors of [Innovotech Inc.](#) (TSX-V: IOT) (“Innovotech” or the “Company”) has appointed Brad Clark as a director of the Company, effective immediately.

Mr. Clark is a seasoned finance professional with over 15 years of experience, holding both Chartered Professional Accountant (CPA) and Chartered Business Valuator (CBV) designations. Specializing in business valuations, tax strategy, and accounting, including international tax structuring, Mr. Clark focuses on scaling growth-oriented companies. Mr. Clark will be granted 50,000 incentive stock options at \$0.18, reflecting the close of market today, and exercisable over five years.

Innovotech has also created an operating company, Innovotech Labs Corporation (“ILC” or “Innovotech Labs”), a wholly owned subsidiary. This new entity encompasses the Company’s contract research, MBEC™ Assay kit production, and antimicrobial silver commercialization activities. This development mirrors the structure established with Innovotech’s other operating company, Keystone Labs Inc., acquired in November 2024.

“With these initiatives, Innovotech is strengthening its operational foundation and establishing a platform for pursuing targeted growth opportunities,” said CEO Craig Milne. “With Mr. Clark’s extensive expertise in finance, M&A, and scaling businesses, the Board gains strategic and technical insight that complements the Company’s focus on innovation and value creation.”

The formation of Innovotech Labs consolidates critical operational activities, enabling streamlined processes and enhanced focus on [contract research](#), [MBEC™ Assay](#) kit production, and commercialization of [InnovoSIL™ Antimicrobial silver](#). [Keystone Labs Inc.](#), a Health Canada, Drug Establishment License (DEL)-accredited lab providing pharmaceutical and other testing services, remains a strong operating core of the group of businesses. Together, these steps are intended to position the Company to continue delivering on high value services to clients, adapt to evolving market demands, and explore new avenues for long-term success.

### **About Innovotech:**

Innovotech Inc. is a diversified Canadian technology company with business operations in



**innovotech**

a growing portfolio of specialized laboratory services, biotechnology businesses, and proprietary intellectual property. Innovotech Inc. manages several subsidiary companies. Innovotech Labs Corporation is a contract research organization that owns and provides proprietary devices for antimicrobial testing in multiple applications and commercializes antimicrobial silver solutions. Learn more at [www.innovotech.ca](http://www.innovotech.ca). Keystone Labs Inc. is a DEL-accredited lab serving the Canadian pharmaceutical industry and industrial markets. Learn more at [www.keystonelabs.ca](http://www.keystonelabs.ca). Innovotech Inc. owns a 60% stake in NouLifeSciences Inc., a company holding intellectual property related to antioxidant molecules with potential applications in cosmetics and various medical conditions including neuropathies.

*Craig Milne, CEO*      **Innovotech Inc.**  
+1-604-239-1819      [craig.milne@innovotech.ca](mailto:craig.milne@innovotech.ca)

*This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company's exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.*

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

###